Table 3 PCR uncorrected treatment outcome
Treatment outcome | Artemether–lumefantrine | Artesunate–amodiaquine | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Doba (n = 31) | Kelo (n = 48) | Kayom (n = 35) | Doba (n = 33) | Kelo (n = 33) | Kayom (n = 35) | |||||||
n (%) | CI 95% | n (%) | 95% CI | n (%) | 95% CI | n (%) | CI 95% | n (%) | 95% CI | n (%) | 95% CI | |
Per-protocol | ||||||||||||
ETF | 0 (0) | 0.0–12.3 | 0 (0) | 0.0–7.4 | 0 (0) | 0.0–10.0 | 0 (0) | 0.0–11.6 | 0 (0) | 0.0–11.2 | 0 (0) | 0.0–10.6 |
LCF | 0 (0) | 0.0–12.3 | 0 (0) | 0.0–7.4 | 0 (0) | 0.0–10.0 | 0 (0) | 0.0–11.6 | 0 (0) | 0.0–11.2 | 0 (0) | 0.0–10.6 |
LPF | 0 (0) | 0.0–12.3 | 4 (8.3) | 2.3–20.0 | 1 (2.9) | 0.1–14.9 | 1 (3.3) | 0.1–17.2 | 0 (0) | 0.0–11.2 | 0 (0) | 0.0–10.6 |
ACPR | 28 (100) | 87.7–100 | 44 (91.7) | 80.0–97.7 | 34 (97.1) | 85.1–99.9 | 29 (96.7) | 82.8–99.9 | 31 (100) | 88.8–100 | 33 (100) | 89.4–100 |
Total per-protocol | 28 | 48 | 35 | 30 | 31 | 33 | ||||||
Withdrawn/lost | 3 (9.7) | 0 (0) | 0 (0) | 3 (9.1) | 2 (6.1) | 2 (5.7) | ||||||
Kaplan–Meier | ||||||||||||
Cure rate | 100 | NA | 91.7 | 79.3–96.8 | 97.1 | 96.7 | 80.4–99.6 | 100 | NA | 100 | NA | |